Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 10, 2015

Primary Completion Date

August 8, 2024

Study Completion Date

March 11, 2025

Conditions
Dyskeratosis CongenitaAplastic Anemia
Interventions
DRUG

Alemtuzumab

Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.

DRUG

Fludarabine

Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.

DRUG

Cyclophosphamide

Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.

RADIATION

Total Body Irradiation

TBI 200 cGy as a single fraction on day -1 from transplant.

BIOLOGICAL

Stem Cell Transplant

Stem cell transplant on day 0.

DRUG

Anti-thymocyte globulin

ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.

Trial Locations (1)

55455

University of Minnesota Medical Center, Fairview, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT02162420 - Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia | Biotech Hunter | Biotech Hunter